Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.69 |
| ▸ | HLCS | P50747 | 3/20 | 0.66 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | IDE | P14735 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 3/20 | 0.63 |
| ▸ | CA1 | P00915 | 3/20 | 0.63 |
| ▸ | CA2 | P00918 | 3/20 | 0.63 |
| ▸ | CA9 | Q16790 | 3/20 | 0.63 |
| ▸ | F2 | P00734 | 1/20 | 0.62 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.62 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.62 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.62 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24179756 | 1.00 | TDP1 (0.69) | TDP1HLCSPKMMEN1ABL1 | |
| SCHEMBL12735634 | 1.00 | TDP1 (0.69) | TDP1HLCSPKMMEN1ABL1 | |
| SCHEMBL22560803 | 1.00 | TDP1 (0.69) | TDP1HLCSPKMMEN1ABL1 | |
| SCHEMBL26551954 | 1.00 | TDP1 (0.69) | TDP1HLCSPKMMEN1ABL1 | |
| SCHEMBL10063351 | 1.00 | TDP1 (0.69) | TDP1HLCSPKMMEN1ABL1 | |
| SCHEMBL17881931 | 0.97 | TDP1 (0.71) | TDP1HLCSPKMMEN1ABL1 | |
| SCHEMBL16923825 | 0.97 | TDP1 (0.71) | TDP1HLCSPKMMEN1ABL1 | |
| SCHEMBL13166618 | 0.96 | TDP1 (0.64) | TDP1HLCSPKMMEN1ABL1 | |
| SCHEMBL17128734 | 0.94 | TDP1 (0.67) | TDP1HLCSPKMMEN1ABL1 | |
| SCHEMBL12085208 | 0.94 | TDP1 (0.70) | TDP1HLCSPKMMEN1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023233024-A1 | DPP9 BINDING COMPOUNDS | UNIVERSITEIT ANTWERPEN (BE) | 2023-12-07 | — | — | WO | disclosed |
| WO-2019170710-A2 | CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE OR ALKYNE-PHOSPHONOTHIOLATES AND -PHOSPHONATES | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019164977-A1 | FLUORINATED NUCLEOTIDES AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-9493444-B2 | Azaheterocyclic compounds | MERCK PATENT GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| WO-2015163952-A1 | ISATOIC ANHYDRIDE DERIVATIVES AND APPLICATIONS THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) | 2015-10-29 | — | — | WO | disclosed |
| US-20150005294-A1 | AZAHETEROCYCLIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-20120226050-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-8207353-B2 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207353-B2 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20080207913-A1 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207913-A1 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080035243-A1 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080035243-A1 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES (US) | 2008-02-14 | — | — | US | disclosed |
| WO-2008006097-A2 | COVALENT MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES LLC (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007127473-A2 | POLY (ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | INTEZYNE TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070054304-A1 | COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION OF PHOSPHORYLATED MOLECULES | INVITROGEN CORPORATION (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054304-A1 | COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION OF PHOSPHORYLATED MOLECULES | INVITROGEN CORPORATION (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080035243-A1 | Covalent modification of metal surfaces | ITGAL, ITGA1, ITGA5 | TDP1 2772/4885HLCS 141/4885PKM 3084/4885 |
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | CD44, CD47, EPCAM | TDP1 3929/4885HLCS 188/4885PKM 1484/4885 |
| US-20150005294-A1 | AZAHETEROCYCLIC COMPOUNDS | PCNA, CDKN1A, CCNC | TDP1 1163/4885HLCS 1165/4885PKM 4031/4885 |
| US-20120226050-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | GNE, EPRS1, ALG1 | TDP1 1487/4885HLCS 119/4885PKM 3080/4885 |
| US-20080207913-A1 | Poly(ethylene glycol) containing chemically disparate endgroups | GNE, EPRS1, ALG1 | TDP1 1487/4885HLCS 119/4885PKM 3080/4885 |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | HDGF, F11, F12 | TDP1 4223/4885HLCS 1229/4885PKM 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.